In a significant shift for women’s health, polycystic ovary syndrome (PCOS) has been renamed polyendocrine metabolic ovarian syndrome (PMOS), reflecting a broader understanding of this often-misunderstood condition. This rebranding is the result of over a decade of advocacy, research, and collaboration among healthcare professionals and patients worldwide, with the aim of improving diagnosis and treatment for millions of women affected by this hormonal disorder.
A Long-Awaited Change
The name change was officially announced at the European Congress of Endocrinology in Prague, following its publication in *The Lancet*. This transformation comes after years of discussions involving various medical and patient organisations across six continents, culminating in a unified effort led by Professor Helena Teede, director of Melbourne’s Monash Centre for Health Research and Implementation.
The term PCOS has long been a source of confusion, often misrepresenting the condition as solely related to ovarian cysts. However, research has demonstrated that PMOS encompasses a multitude of hormonal imbalances affecting various systems, including metabolism and cardiovascular health. Teede emphasised that the previous terminology failed to adequately represent the “multi-system burden” experienced by those diagnosed with the condition.
Understanding PMOS
Maddy Mavrikis, a Sydney resident and one of the many individuals sharing their experiences, reflects on her own journey with PMOS. Diagnosed at 15, she was initially told by her GP that she may never conceive—a statement she later learned was misleading. Mavrikis’ experience illustrates a common theme among women with PMOS: the need to unlearn misconceptions associated with their diagnosis.
Initially seeking help for irregular menstrual cycles, Mavrikis was shocked to discover she had elevated androgen levels, leading to various symptoms including acne and excessive hair growth. The mischaracterisation surrounding “polycystic ovaries” further complicated her understanding, as many women can be diagnosed without actually having cysts.
The Role of Patient Advocacy
The push for renaming PCOS to PMOS emerged from a growing demand for recognition of the broader implications of the disorder. Patients expressed their frustrations with the previous misconceptions associated with PCOS, arguing that the outdated name contributed to inadequate care. Teede noted the importance of patient voices in this process, stating, “They wanted it fixed… they were really passionate.”
This initiative has been a long time coming. Academic discussions regarding a name change have been underway since 1995, with a recommendation from the US National Institutes of Health in 2012. The comprehensive approach taken to reach consensus across 56 medical and patient societies marks a new era in how health conditions are addressed.
Looking Forward
The shift from PCOS to PMOS is not just a semantic adjustment; it represents a commitment to better patient care and understanding. As the change is set to be fully integrated into international guidelines by 2028, it signifies a hopeful new chapter for the 170 million women globally who live with this condition.
Mavrikis, alongside other advocates like Lorna Berry, who has campaigned for improved education on the disorder for over 25 years, is optimistic about this transformation. Berry highlighted the robust nature of the discussions surrounding the name change, illustrating a newfound respect for the experiences and perspectives of those living with PMOS.
Why it Matters
Renaming PCOS to PMOS is more than just a change in terminology; it is a powerful statement affirming the need for improved healthcare for women. This rebranding acknowledges the comprehensive nature of the condition and aims to foster a greater understanding among medical professionals, ultimately leading to better diagnosis and treatment. As awareness grows, so too does the hope that the healthcare system will evolve to better support women navigating the complexities of PMOS, reducing stigma and enhancing quality of life for millions.